Rhythm Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases.

CEO

David P. Meeker

CEODavid P. Meeker

Employees

414

Employees414

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

2008

Founded2008

Employees

414

Employees414

RYTM Key Statistics

Market cap

8.53B

Market cap8.53B

Price-Earnings ratio

-35.73

Price-Earnings ratio-35.73

Dividend yield

—

Dividend yield—

Average volume

849.02K

Average volume849.02K

High today

$116.09

High today$116.09

Low today

$111.69

Low today$111.69

Open price

$112.92

Open price$112.92

Volume

350.97K

Volume350.97K

52 Week high

$122.20

52 Week high$122.20

52 Week low

$74.50

52 Week low$74.50

Stock Snapshot

Rhythm Pharmaceuticals(RYTM) stock is priced at $113.57, giving the company a market capitalization of 8.53B. It carries a P/E multiple of -35.73.

During the trading session on 2026-08-07, Rhythm Pharmaceuticals(RYTM) shares reached a daily high of $116.09 and a low of $111.69. At a current price of $113.57, the stock is +1.7% higher than the low and still -2.2% under the high.

Trading volume for Rhythm Pharmaceuticals(RYTM) stock has reached 350.97K, versus its average volume of 849.02K.

Over the past 52 weeks, Rhythm Pharmaceuticals(RYTM) stock has traded between a high of $122.20 and a low of $74.50.

RYTM News

Simply Wall St 22h

How Investors May Respond To Rhythm Pharmaceuticals Q2 Results And Early RM-718 Obesity Data - simplywall.st

...

TipRanks 1d

EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus

Rhythm Pharmaceuticals (RYTM) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more...

TipRanks 2d

Rhythm Pharmaceuticals Inc Q4 2022 Earnings Report - Results, Call & Slides - TipRanks

...

Analyst ratings

94%

of 17 ratings

Buy

94.1%

Hold

5.9%

Sell

More RYTM News

TipRanks 3d

Rhythm Pharmaceuticals Earnings Call Signals Momentum

Rhythm Pharmaceuticals ((RYTM)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing too...

TipRanks 3d

Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 3d

Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial

Rhythm Pharmaceuticals (RYTM) announced preliminary results from the ongoing Phase 2 trial evaluating RM-718, Rhythm’s investigational once-weekly MC4R agonist,...

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…

AMD

Eli Lilly

Rocket Lab Corporation

Broadcom

Robinhood Markets

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.